RxDoctor Payments Data

Mary Pena, MD

Neurology · Humacao, PRNPI 1386746634

Payments from drug & device makers

$960in general payments, 2019–2025

Across 49 payments — averaging $19.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Acadia Pharmaceuticals Inc$247
  • Biogen$237
  • Adamas Pharmaceuticals, Inc.$194
  • E.r. Squibb & Sons, L.L.C.$147
  • AbbVie$103
  • Pfizer Pharmaceuticals LLC$32

What the payments were for

  • Food & beverage$89593%
  • Education$657%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Acadia Pharmaceuticals Inc15$247
Biogen11$237
Adamas Pharmaceuticals, Inc.12$194
E.r. Squibb & Sons, L.L.C.5$147
AbbVie4$103
Pfizer Pharmaceuticals LLC2$32

How this compares

$960 in reported general payments places this provider in the 40th percentile of 129 neurology providers in Puerto Rico.

See all neurology providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$7,670
Medicare patients
31
Services billed
44

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NuplazidPimavanserin Tartrate86$433,740
TecfideraDimethyl Fumarate24$227,402
Emgality PenGalcanezumab-Gnlm173$124,489
CopaxoneGlatiramer Acetate15$86,343
BotoxOnabotulinumtoxina68$85,191
KeppraLevetiracetam40$73,585
Glatiramer Acetate14$37,635
Rivastigmine238$26,938
Aimovig AutoinjectorErenumab-Aooe28$21,454
Nurtec OdtRimegepant Sulfate16$19,964
NeuproRotigotine22$19,033
GocovriAmantadine Hcl11$17,739
Memantine Hcl1,180$17,023
LamictalLamotrigine19$16,564
Tegretol XrCarbamazepine45$15,688

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Acadia Pharmaceuticals IncNuplazid$247$433,74086 claims
BiogenTecfidera$237$227,40224 claims
AbbVieBotox$103$85,19168 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 129 neurology providers in Puerto Rico.

Other neurology in Humacao

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →